Cogito: a turnkey platform to quickly build digital therapeutics for substance use disorders
Cogito: A Turnkey Solution for Rapidly Developing, Evaluating, Deploying, and Scaling Digital Therapeutics
This project will test whether PhD- or MD-level SUD researchers can easily create and customize digital therapeutic content for substance use disorders using the Cogito drag-and-drop platform.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Square2 Systems, Inc. Industry-sponsored |
| Locations | 1 site (Hanover, New Hampshire) |
| Trial ID | NCT07104396 on ClinicalTrials.gov |
What this trial studies
This observational usability study asks experienced SUD researchers to use the Cogito platform to build sample guides, activities, and surveys via an interactive tutorial and a guided "functionality scavenger hunt." Participants complete tasks within the platform and then fill out surveys to provide structured feedback on usability and functionality. The goal is to identify usability issues and improvement opportunities for Cogito when used to create digital therapeutics for substance use disorders. The study is sponsored by Square2 Systems with collaboration from NIDA and conducted at Square2 Systems in Hanover, New Hampshire.
Who should consider this trial
Good fit: Ideal participants are PhD- or MD-level scientists (or equivalent) at the postdoctoral level or higher who are trained in SUD research and have a stated interest in digital therapeutics for SUDs.
Not a fit: People who are not researchers (or who lack SUD research training), are under 18, or do not have an interest in digital therapeutics are unlikely to benefit from participating.
Why it matters
Potential benefit: If successful, Cogito could lower the technical barrier and speed development of evidence-based digital therapeutics for SUDs, enabling more rapid deployment and iteration of behavioral interventions.
How similar studies have performed: Usability studies of other digital health authoring tools have shown feasibility and helpful feedback, but Cogito's turnkey drag-and-drop approach for SUD-specific digital therapeutics represents a novel, initially untested implementation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * At least 18 years * PhD and/or MD-level (or equivalent) scientists at academic institutions or digital health companies at the level of Post-doctoral Fellow or higher. * Training or trained in substance use disorder (SUDs) research. * Must state a specific interest in digital therapeutics for SUDs. Exclusion Criteria: * Those who do not meet inclusion criteria.
Where this trial is running
Hanover, New Hampshire
- Square 2 Systems — Hanover, New Hampshire, United States (Recruiting)
Study contacts
- Study coordinator: Square2 Systems
- Phone: (802) 526-4608
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.